Retrophin Inc. (RTRX) Receives Consensus Rating of “Buy” from Brokerages
Shares of Retrophin Inc. (NASDAQ:RTRX) have earned a consensus recommendation of “Buy” from the six analysts that are covering the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $28.40.
A number of research firms have commented on RTRX. JMP Securities reaffirmed a “buy” rating on shares of Retrophin in a research report on Saturday, July 9th. Zacks Investment Research downgraded shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Tuesday, August 2nd. Leerink Swann reissued a “buy” rating and set a $27.00 price objective on shares of Retrophin in a research report on Monday, June 27th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $28.00 price objective (up previously from $25.00) on shares of Retrophin in a research report on Monday, August 8th.
Shares of Retrophin (NASDAQ:RTRX) traded down 1.89% during midday trading on Wednesday, reaching $20.26. The company had a trading volume of 199,577 shares. Retrophin has a one year low of $11.60 and a one year high of $24.57. The company has a market capitalization of $744.17 million, a PE ratio of 8.23 and a beta of 1.02. The company has a 50 day moving average of $21.59 and a 200 day moving average of $18.04.
Retrophin (NASDAQ:RTRX) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.30. Retrophin had a net margin of 83.57% and a negative return on equity of 0.52%. The business earned $33.30 million during the quarter, compared to the consensus estimate of $32.73 million. The company’s revenue for the quarter was up 38.2% on a year-over-year basis. Analysts predict that Retrophin will post $0.09 EPS for the current fiscal year.
In related news, EVP Alvin Shih sold 8,750 shares of the company’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $16.24, for a total value of $142,100.00. Following the completion of the transaction, the executive vice president now owns 158,334 shares of the company’s stock, valued at approximately $2,571,344.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.41% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Teachers Advisors Inc. increased its position in shares of Retrophin by 14.3% in the first quarter. Teachers Advisors Inc. now owns 231,492 shares of the biopharmaceutical company’s stock valued at $3,162,000 after buying an additional 28,956 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Retrophin by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,302,989 shares of the biopharmaceutical company’s stock valued at $17,799,000 after buying an additional 22,903 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Retrophin during the first quarter valued at $1,046,000. Scopia Capital Management LP increased its position in shares of Retrophin by 874.8% in the first quarter. Scopia Capital Management LP now owns 3,598,222 shares of the biopharmaceutical company’s stock valued at $49,152,000 after buying an additional 3,229,087 shares in the last quarter. Finally, GW&K Investment Management LLC increased its position in shares of Retrophin by 12.2% in the second quarter. GW&K Investment Management LLC now owns 95,987 shares of the biopharmaceutical company’s stock valued at $1,710,000 after buying an additional 10,465 shares in the last quarter.
Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.